Scandion Oncology CEO Newsletter November 2019
Dear Scandion Oncology shareholder,Being able to change drug resistance will have impact on millions of cancer patients world-wide. With the current speed of development and if everything works out, we expect to start the clinical phase II study with SCO-101 treatment by December 2019. In this newsletter, I will give a short summary of what’s to come for SCO-101, with a primary focus on the upcoming phase II clinical trial.Clinical phase II study in patients with drug resistant metastatic colorectal cancerThis is our first clinical study where drug resistant cancer patients will be